Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Linagliptin in Renal Transplant Recipients with Diabetes
NCT06095492Recruiting
- Sponsor
- Medanta
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in diabetes mellitus (DM) (2 arms), sponsored by Medanta. Primary endpoints: Estimated Glomerular Filtration Rate at 12 months, Urine Albumin-Creatinine Ratio at 12 months and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06095492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095492.